U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H16N2O5.ClH
Molecular Weight 292.716
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALAGLUMETAD HYDROCHLORIDE

SMILES

Cl.[H][C@@]12CC[C@@](NC(=O)[C@H](C)N)(C(O)=O)[C@]1([H])[C@H]2C(O)=O

InChI

InChIKey=TWZDLCLCMKMJPE-OAOSNHGPSA-N
InChI=1S/C11H16N2O5.ClH/c1-4(12)8(14)13-11(10(17)18)3-2-5-6(7(5)11)9(15)16;/h4-7H,2-3,12H2,1H3,(H,13,14)(H,15,16)(H,17,18);1H/t4-,5-,6-,7-,11-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800008428 https://en.wikipedia.org/wiki/Eglumegad https://www.ncbi.nlm.nih.gov/pubmed/17712352 https://www.ncbi.nlm.nih.gov/pubmed/17204749

Talaglumetad (also known as LY-544344) is a bicyclohexane derivative patented by Eli Lilly and Company as modulators of metabotropic glutamate receptor. Talaglumetad acts as a prodrug of Eglumegad, a selective agonist of metabotropic glutamate receptors (mGluR2/3) and metabolized to release active compound by both human jejunal homogenates and rat liver homogenates. In experiments on mice, Talaglumetad was found to be as effective as diazepam for treating anxiety symptoms in several standard tests, but without producing any of the negative side effects of diazepam such as sedation and memory impairment.

Approval Year

Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 18
Health Status: unhealthy
Condition: panic disorder
Sex: M+F
Food Status: UNKNOWN
Population Size: 18
Sources:
Disc. AE: headache, Nausea...
AEs leading to
discontinuation/dose reduction:
headache (1 pt)
Nausea (1 pt)
allergic reaction (2 patients)
Dizziness (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 1 pt
Disc. AE
200 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 18
Health Status: unhealthy
Condition: panic disorder
Sex: M+F
Food Status: UNKNOWN
Population Size: 18
Sources:
Nausea 1 pt
Disc. AE
200 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 18
Health Status: unhealthy
Condition: panic disorder
Sex: M+F
Food Status: UNKNOWN
Population Size: 18
Sources:
headache 1 pt
Disc. AE
200 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 18
Health Status: unhealthy
Condition: panic disorder
Sex: M+F
Food Status: UNKNOWN
Population Size: 18
Sources:
allergic reaction 2 patients
Disc. AE
200 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 18
Health Status: unhealthy
Condition: panic disorder
Sex: M+F
Food Status: UNKNOWN
Population Size: 18
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
1998 Oct
The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity.
2000
The role of striatal metabotropic glutamate receptors in Parkinson's disease.
2002
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 8 or 16 mg twice per day (LY544344). LY544344 is a LY354740 prodrug that increases LY354740 bioavailability. https://www.ncbi.nlm.nih.gov/pubmed/17712352
100 or 200 mg (LY354740)
Route of Administration: Oral
LY354740 failed to inhibit Dopamine D(2) receptor binding in both native striatal tissue homogenates and cloned receptors at concentrations up to 10 uM.
Name Type Language
TALAGLUMETAD HYDROCHLORIDE
USAN  
USAN  
Official Name English
LY544344 HYDROCHLORIDE
Code English
TALAGLUMETAD HCL
Common Name English
(1S,2S,5R,6S)-2-[[(2S)-2-Aminopropanoyl]amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride
Systematic Name English
TALAGLUMETAD MONOHYDROCHLORIDE
Common Name English
LY-544344 HYDROCHLORIDE
Code English
TALAGLUMETAD HYDROCHLORIDE [USAN]
Common Name English
BICYCLO(3.1.0)HEXANE-2,6-DICARBOXYLIC ACID, 2-(((2S)-2-AMINO-1-OXOPROPYL)AMINO), MONOHYDROCHLORIDE, (1S,2S,5R,6S)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28197
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID40963180
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
SMS_ID
300000044511
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
USAN
PP-78
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL1189257
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
NCI_THESAURUS
C81620
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
CAS
441765-97-5
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
PUBCHEM
9857255
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY
FDA UNII
X30300EU7I
Created by admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
PRIMARY